You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》野村首予先聲藥業(02096.HK)「買入」評級 目標價10.1元
阿思達克 04-19 10:13
野村發表報告指,先聲藥業(02096.HK)治療中樞神經系統疾病及自體免疫性疾病的藥物銷售增長,將帶動2021年至2023年收入及盈利分別以20%及22%的年複合率增長。該行料治療中樞神經系統疾病的藥物於今年將貢獻11.77億元人民幣銷售額,明年貢獻16.42億元人民幣,2023年則貢獻18.3億元人民幣。相信「先必新」及替代「必存」在去年獲納入國家藥監局名單後,相信將快速增長,以搶佔「必存」流失的市佔率。

該行首予先聲藥業「買入」評級,目標價10.1元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account